Compare CTNM & XMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTNM | XMAX |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Home Furnishings |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 489.4M | 534.9M |
| IPO Year | 2024 | N/A |
| Metric | CTNM | XMAX |
|---|---|---|
| Price | $15.00 | $8.90 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | 417.0K | ★ 2.6M |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.72 | $8.10 |
| 52 Week High | $16.33 | $8.89 |
| Indicator | CTNM | XMAX |
|---|---|---|
| Relative Strength Index (RSI) | 68.54 | 77.64 |
| Support Level | $11.82 | N/A |
| Resistance Level | $15.60 | N/A |
| Average True Range (ATR) | 1.08 | 0.43 |
| MACD | 0.35 | 0.07 |
| Stochastic Oscillator | 88.91 | 93.63 |
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.